Protagonist Therapeutics, Inc (PTGX) Stock Price

PTGXStock

$150.59+169.17%52W

Market Cap$9.74B

P/E21.85x

PEG Ratio—

Div yield—

Beta1.50

PTGX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)75.19%

Price vs S&P 500 (4W)10.01%

VGM Score56.86

P/E Ratio (Annual)21.85x

P/CF (Annual)172.18x

Book Value / Share (Quarterly)$13.01

P/TBV (Annual)4.61x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)20.07%

Cash Flow / Share (Quarterly)$2.02

Price vs S&P 500 (YTD)65.19%

Net Profit Margin (TTM)29.40%

EPS (TTM)$1.04

10-Day Avg Trading Volume0.48M

EPS Excl Extra (TTM)$1.04

Revenue Growth (5Y)9.96%

EPS (Annual)$-2.05

ROI (Annual)-21.17%

Net Profit Margin (5Y Avg)-257.85%

Cash / Share (Quarterly)$12.10

P/E Basic Excl Extra (TTM)119.77x

Revenue Growth QoQ (YoY)3749.17%

P/E Normalized (Annual)21.85x

ROA (Last FY)-19.48%

Revenue Growth TTM (YoY)34.81%

EBITD / Share (TTM)$0.89

ROE (5Y Avg)-20.96%

Operating Margin (TTM)20.69%

Cash Flow / Share (Annual)$0.90

P/B Ratio11.80x

P/B Ratio (Quarterly)9.37x

Net Income / Employee (Annual)$-986,000

EV / Revenue (TTM)33.72x

Net Interest Coverage (TTM)-7.30x

ROA (TTM)11.23%

EV / EBITDA (TTM)158.81x

EPS Incl Extra (Annual)$-2.05

Current Ratio (Annual)12.71x

Quick Ratio (Quarterly)21.58x

3-Month Avg Trading Volume0.65M

52-Week Price Return169.17%

EV / Free Cash Flow (Annual)169.57x

P/E Incl Extra (TTM)119.77x

Revenue / Employee (TTM)$2,136,300

Tangible BV / Share (Quarterly)$5.24

P/S Ratio (Annual)215.79x

Asset Turnover (Annual)0.07x

52-Week High$160.81

Operating Margin (5Y Avg)-279.15%

EPS Excl Extra (Annual)$-2.05

CapEx CAGR (5Y)27.60%

Tangible BV CAGR (5Y)12.32%

26-Week Price Return86.43%

Quick Ratio (Annual)12.58x

13-Week Price Return51.67%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)21.71x

Enterprise Value$9.51B

Revenue / Share Growth (5Y)-2.75%

Asset Turnover (TTM)0.38x

Book Value / Share Growth (5Y)8.95%

Revenue / Employee (Annual)$348,600

Pretax Margin (Annual)-281.01%

Cash / Share (Annual)$9.07

3-Month Return Std Dev46.77%

Net Income / Employee (TTM)$628,100

ROE (Last FY)-21.17%

Net Interest Coverage (Annual)-376.80x

EPS Basic Excl Extra (Annual)$-2.05

P/FCF (TTM)45.37x

Receivables Turnover (TTM)16.54x

EV / Free Cash Flow (TTM)72.83x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$1.04

Receivables Turnover (Annual)9.87x

ROI (TTM)12.03%

P/S Ratio (TTM)35.21x

Pretax Margin (5Y Avg)-257.29%

Revenue / Share (Annual)$0.72

Tangible BV / Share (Annual)$4.37

Forward P/E87.06x

Price vs S&P 500 (52W)150.86%

P/E Ratio (TTM)119.77x

EPS Growth TTM (YoY)45.97%

Year-to-Date Return77.15%

5-Day Price Return-1.67%

EPS Normalized (Annual)$-2.05

ROA (5Y Avg)-18.42%

Net Profit Margin (Annual)-282.83%

Month-to-Date Return13.23%

Cash Flow / Share (TTM)$-2.59

EBITD / Share (Annual)$-2.47

Operating Margin (Annual)-343.63%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)75.69x

ROI (5Y Avg)-20.96%

P/E Excl Extra (TTM)119.77x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$1.04

P/TBV (Quarterly)3.29x

P/B Ratio (Annual)8.88x

Pretax Margin (TTM)29.91%

Book Value / Share (Annual)$9.82

Price vs S&P 500 (13W)48.88%

Beta1.50x

P/FCF (Annual)177.06x

Revenue / Share (TTM)$3.97

ROE (TTM)12.03%

52-Week Low$54.50

vGradeF

gGradeB

mGradeA

vgmGradeC

PTGX Earnings Surprise History

Q2 25-0.55est. -0.52

Q3 25-0.62est. -0.64

Q4 25-0.69est. -0.54

Q1 260.05est. -0.65

Q2 262.29est. 1.93

PTGX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.21

4.25

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Protagonist Therapeutics, Inc

Protagonist Therapeutics is a biopharmaceutical company developing peptide-based therapeutics across inflammation, hematology, and metabolic diseases using a proprietary platform. Its clinical pipeline includes rusfertide for polycythemia vera and icotrokinra for inflammatory conditions, complemented by preclinical programs in obesity and iron metabolism. The company advances its candidates through internal research and strategic collaborations.